6998 (6998) Fair Value & Analysis

Healthcare · Market cap HK$3.5B

6 6998 6998 · HK

PriceHK$1.75

Fair ValueHK$4.51

Upside+157.7%

Quality32/100

Watch 6998 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$3.11 – HK$6.55

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −6.4% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.61 – HK$5.52 · fair‑value band HK$3.11 – HK$6.55 · the HK$1.75 price screens below the HK$4.51 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6998 (6998) currently trades at HK$1.75, while our model-based Fair Value estimate is HK$4.51 — implying the stock looks roughly 157.7% undervalued today. We read business quality at 32/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 6998 generated revenue of HK$2.5B at a net margin of 16.1%. Revenue grew 15.3% year over year. It earns a return on equity of 12.8%. Net debt stands at HK$431M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$2.5B

Revenue growth (YoY) +15.3%

Net margin 16.1%

Return on equity 12.8%

Free cash flow HK$404M FY2025

P/E ratio 6.5

More key figures

Operating margin 26.4%

EPS (TTM) HK$-0.1000

EPS growth (YoY) +104%

Net debt HK$431M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6998 reported revenue of HK$2.7B in FY2025 versus HK$0 in FY2021. Reported net income was HK$433M in FY2025.

Revenue

FY21 HK$0

FY22 HK$18.5M

FY23 HK$0

FY24 HK$2.8B

FY25 HK$2.7B

Net income

FY21 −HK$1.0B

FY22 −HK$849M

FY23 −HK$745M

FY24 HK$421M

FY25 HK$433M

Is 6998 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.01	¥26.59	-43%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.58	HK$18.75	-37%
Divi's Laboratories Limited DIVISLAB	₹6,788	₹2,035	-70%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6998 (6998) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$4.51 versus a price of HK$1.75 — about +158% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 6998?

Our model-based fair value for 6998 is HK$4.51 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.75.

What is the quality score of 6998?

6998 has a Quality Score of 32/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6998 (6998)?

6998 reported trailing-twelve-month revenue of about HK$2.5B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6998?

The net profit margin of 6998 is about 16.1%, meaning it keeps roughly 16.1% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.